Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05466851 · ClinicalTrials.gov registry record
An Exploratory Study Examining Biopsychosocial Markers of Anxiety and Depression
A clinical trial of Depression and Anxiety Disorders, sponsored by Singula Institute.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05466851: Recruiting study of Depression and Anxiety Disorders, sponsored by Singula Institute.
NCT05466851 is a study of Depression and Anxiety Disorders that is actively recruiting participants, run by Singula Institute. The registered enrollment target is 200 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05466851, a study of Depression and Anxiety Disorders, is actively recruiting participants, sponsored by Singula Institute.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying how thoughts, feelings, surroundings, and individual biology may contribute to why and how people experience anxiety or depression. We are trying to find out the wide variety of reasons that people may experience anxiety or depression, and why different people are helped by different forms of treatment. We are trying to determine why people stay in treatment, and what factors contribute to a positive or negative response to treatment. These reasons may be due to thoughts, feelings, beliefs, personality, biology, social support network, life events, and barriers to treatment. A wide range of information about factors that impact anxiety and depression will be included. These include, among others, measures of inflammation, hormone levels, behavior, spoken language, personality, medical history, social determinants of health, and attitudes toward mental health and its treatment. The study involves psychological and psychiatric treatments in the form of psychotherapy and medication management. The participant will be asked to set specific goals for study treatment, and to provide videos between sessions about relevant medication, emotional, and sleep factors in their life. In summary, this study will collect biological, psychological, and social factors that may play a role in anxiety and depression. This will inform both individual's diagnosis and treatment and will be used in a later set of analyses that can inform diagnosis and treatment for other individuals who share similar characteristics.
Primary Outcome
To identify biopsychosocial correlates of treatment engagement and adherence through Neurocognitive measures of cognitive flexibility (cognitive control, executive functioning, task inhibition) and delayed gratification, biological markers of stress and inflammation, perceived psychological stress, anxiety, mood, loneliness, and stigma, and video recorded affective responses to prompts.
Conditions Studied
Study Locations (1)
New York
- Singula Institute, 353 Lexington Avenue (Room 600) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2032-03-31 |
What NCT05466851 shows while recruiting
NCT05466851 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 0 interventions.
NCT05466851 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05466851 about?
NCT05466851 is a clinical study titled "An Exploratory Study Examining Biopsychosocial Markers of Anxiety and Depression". This research study is studying how thoughts, feelings, surroundings, and individual biology may contribute to why and how people experience anxiety or depression. We are trying to find out the wide variety of reasons that people may experience anxiety or depression, and why different people are he...
What is the current status of trial NCT05466851?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-03-01. Estimated completion is 2032-03-31.
What conditions does trial NCT05466851 study?
This clinical trial studies the following conditions: Depression, Anxiety Disorders, Stress Related Disorder.
Who is sponsoring clinical trial NCT05466851?
This trial is sponsored by Singula Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05466851 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05466851's enrollment target sits among peer trials
200 209th of 679 higher than 465 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy